Literature DB >> 24304979

The multiple roles of guanylate cyclase C, a heat stable enterotoxin receptor.

Kris A Steinbrecher1.   

Abstract

PURPOSE OF REVIEW: Guanylate cyclase C (GC-C) is a transmembrane receptor that is expressed primarily on intestinal epithelial cells. Activation of this receptor by its endogenous peptide ligands initiates cyclic guanosine monophosphate-dependent (cGMP) salt and water movement in the intestine. GC-C is targeted by the enterotoxigenic Escherichia coli heat-stable enterotoxin STa, which deregulates this pathway and causes secretory diarrhea. This review discusses current work on the physiological function of GC-C in the intestine. RECENT
FINDINGS: Familial GC-C mutations demonstrate that epithelial cGMP signaling is critical to electrolyte and fluid balance in the neonatal intestine. Chronic deregulation of GC-C activity in early life increases susceptibility to a number of disorders, including obstruction and inflammatory bowel disease. Murine models indicate that GC-C regulates the composition of intestinal commensal microflora and that it suppresses bacterial infection and modulates colonic injury and inflammation. Therapeutic GC-C ligands are used to successfully treat constipation-predominant irritable bowel syndrome and recent studies show that extracellular cGMP is an important mechanism of reducing abdominal pain associated with this disorder.
SUMMARY: Originally identified as a target of E. coli enterotoxin STa, GC-C is an important regulator of physiological salt and water homeostasis and may directly impact a wide range of intestinal disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24304979     DOI: 10.1097/MOG.0000000000000020

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  8 in total

Review 1.  Animal Enterotoxigenic Escherichia coli.

Authors:  J Daniel Dubreuil; Richard E Isaacson; Dieter M Schifferli
Journal:  EcoSal Plus       Date:  2016-10

2.  Reply from L. P. Cid, T. J. Jentsch and F. V. Sepúlveda: intestinal electrolyte and fluid secretion - a model in trouble?

Authors:  L P Cid; T J Jentsch; F V Sepúlveda
Journal:  J Physiol       Date:  2018-04-16       Impact factor: 5.182

3.  Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.

Authors:  Kunwar Shailubhai; Vaseem Palejwala; Krishna Priya Arjunan; Sayali Saykhedkar; Bradley Nefsky; John A Foss; Stephen Comiskey; Gary S Jacob; Scott E Plevy
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

4.  Guanylate cyclase C reduces invasion of intestinal epithelial cells by bacterial pathogens.

Authors:  Surya Amarachintha; Eleana Harmel-Laws; Kris A Steinbrecher
Journal:  Sci Rep       Date:  2018-01-24       Impact factor: 4.379

5.  Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog.

Authors:  Andrea Brancale; Kunwar Shailubhai; Salvatore Ferla; Antonio Ricci; Marcella Bassetto; Gary S Jacob
Journal:  Pharmacol Res Perspect       Date:  2017-03-12

6.  Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models.

Authors:  Illona-Marie Boulete; Anusha Thadi; Catherine Beaufrand; Viren Patwa; Apoorva Joshi; John A Foss; E Priya Eddy; Helene Eutamene; Vaseem A Palejwala; Vassilia Theodorou; Kunwar Shailubhai
Journal:  World J Gastroenterol       Date:  2018-05-07       Impact factor: 5.742

7.  Proliferation of enterotoxigenic Escherichia coli strain TW11681 in stools of experimentally infected human volunteers.

Authors:  Oda Barth Vedøy; Kurt Hanevik; Sunniva Todnem Sakkestad; Halvor Sommerfelt; Hans Steinsland
Journal:  Gut Pathog       Date:  2018-10-16       Impact factor: 4.181

Review 8.  Pig vaccination strategies based on enterotoxigenic Escherichia coli toxins.

Authors:  J Daniel Dubreuil
Journal:  Braz J Microbiol       Date:  2021-07-10       Impact factor: 2.476

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.